Onco-Innovations Launches Key Polymer Process for ONC010

Onco-Innovations Limited, based in Vancouver, has commenced a polymer process development with Nanosoft Polymers. This initiative supports ONC010, their leading Polynucleotide Kinase Phosphatase (PNKP) inhibitor. Key activities include polymer synthesis optimization and characterization methodology, aiming to create a scalable polymer manufacturing process. This forms a crucial part of Onco's chemistry, manufacturing, and controls strategy.

CEO Thomas O'Shaughnessy emphasized the importance of this collaboration with Nanosoft in enhancing ONC010's manufacturing and formulation capabilities. Nanosoft's experience in polymer science is pivotal in advancing GMP manufacturing and clinical development.

Dr. Islam Mohamed, Chief Medical Officer, highlighted the significance of robust polymer characterization in developing nanoparticle-based oncological therapies. This collaboration aims to prepare Onco-Innovations for future regulatory and clinical developments.